Skip to main content

Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS

Journal
Transplantation and Cellular Therapy (Q1)
Published
12 June 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Uday R Popat, Konstantinos Lontos, Roland Bassett, Jitesh Kawedia, Ben C Valdez, Alison M Gulbis, et al.
PMID
42285355
DOI
10.1016/j.jtct.2026.06.014

Why clinicians should know about it

  • Picked for Hematology (top studies of the week, 22 November 2026): Randomized comparison of AML/MDS transplant conditioning regimens

Abstract

BACKGROUND: A myeloablative busulfan and fludarabine regimen that includes fractionating busulfan and extending its delivery time results in low toxicity, permitting its use in stem cell transplant recipients who would otherwise receive reduced intensity conditioning. Cladribine is an active agent in AML that may synergize with fludarabine. OBJECTIVE: This phase two randomized trial examined if additional busulfan fractionation improved the efficacy and safety of a cladribine and fludarabine-containing regimen. STUDY DESIGN: AML or MDS patients, 18-70 years-old, with a matched donor were randomized to two arms; arm A contained outpatient busulfan 80mg/m2 on days -13 and -12, arm B contained outpatient busulfan 80mg/m2 on days -20 and -13. The remaining regimen for both groups included fludarabine 10mg/m2, cladribine 10mg/m2 and busulfan pharmacokinetically-dosed for total exposure of 20,000±12%µmol.min on days -6 to -3. The primary outcome was progression-free survival (PFS) (ClinicalTrials.gov: NCT02250937). RESULTS: 116 patients were randomized; 59 and 57 to arms A and B, respectively. Three-year PFS was 48.7% (95%CI; 37.4-63.4) in arm A and 61.3% (49.9-75.4) in arm B (p=0.19). More patients in arm A experienced grade ≥3 toxicities compared with arm B, 93.2% versus 73.7% (p=0.005). Three-year non-relapse mortality was 19% (8.7-29.2) and 7% (0.3-13.7) (p=0.066) and three-year relapse rate was 32.3% (20.2-44.4) and 31.7% (19.4-43.9) (p=0.99) in arms A and B, respectively. A multivariate Bayesian regression analysis supported an overall and progression free survival benefit in the longer-duration arm B. CONCLUSION: This busulfan, fludarabine, and cladribine regimen, with 3 weeks of busulfan fractionation, appears safe and effective. Furthermore, fractionation of busulfan and giving it over a 3-week period reduces toxicity without increasing relapse rate, allowing safe delivery of a myeloablative regimen to older patients.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.